Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager or BiTE with two arms to latch onto CD20. Unique to glofitamab-gxbm is its administration approach of a “fixed duration” lasting about 8.5 months.
The drug is indicated for relapsed or refractory diffuse large B-cell lymphoma or large B-cell lymphoma arising from follicular lymphoma or after lines of systemic therapy.